CEVI — CellaVision AB Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapFalling Star

Annual income statement for CellaVision AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	SAS	SAS	SAS	SAS	SAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	471	566	639	677	723
Cost of Revenue
Gross Profit	313	392	438	463	487
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	361	403	481	510	546
Operating Profit	110	163	158	167	178
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	112	158	148	164	177
Provision for Income Taxes
Net Income After Taxes	89.5	125	118	130	141
Net Income Before Extraordinary Items
Net Income	89.5	125	118	130	141
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	89.5	125	118	130	141
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.87	5.25	5.07	5.46	5.9
Dividends per Share